Answers are grounded in this paper and cite their sources.
Objective Immune checkpoint inhibitor (ICI) plus angiogenesis inhibitor (AI) combination therapy is a novel treatment model for multiple cancers that normalizes vascular-immune crosstalk to potentiate cancer immunity. In this review, we summarize the characteristics of adverse effects (AEs) and all fatal cases reported in clinical studies involing ICI + AI therapy. Methods Four databases were systematically searched for eligible studies, and 28 relevant studies were selected for inclusion. Results Of the patients included, 58.1% developed grade ≥ 3 AEs. The most common fatal AEs were cardiovascular events, severe infections, and hemorrhage. Compared with AI alone, ICI + AI therapy resulted in more cases of grade ≥ 3 proteinuria, liver injury, and fatal AEs (2.49% vs. 1.28%, P = 0.0041), especially respiratory toxicities and severe infections; however, ICI + AI therapy reduced hematological toxicity. Conclusion We shared comprehensive and practical safety data to review the adverse events associated with ICI + AI treatment.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: